GDF-15 and soluble ST2 as biomarkers of right ventricular dysfunction in pulmonary hypertension

Biomark Med. 2022 Dec;16(17):1193-1207. doi: 10.2217/bmm-2022-0395. Epub 2023 Feb 15.

Abstract

Background: This study analyzed the utility of soluble ST2 (sST2) and GDF-15 as biomarkers of right ventricular (RV) function in patients with pulmonary hypertension (PH). Methods: GDF-15 and sST2 serum concentrations were measured in patients with PH (n = 628), dilated cardiomyopathy (n = 31) and left ventricular hypertrophy (n = 47), and in healthy controls (n = 61). Results: Median sST2 and GDF-15 levels in patients with left ventricular hypertrophy were higher than in patients with PH and dilated cardiomyopathy. In tertile analysis GDF-15 >1363 pg/ml and sST2 >38 ng/ml were associated with higher N-terminal pro-brain natriuretic peptide, RV systolic dysfunction, RV-pulmonary arterial uncoupling and hemodynamic impairment. Conclusion: GDF-15 and sST2 are potential biomarkers of RV dysfunction in patients with PH.

Keywords: biomolecules; chronic thromboembolic pulmonary hypertension; dilated cardiomyopathy; fibrosis; heart failure; idiopathic pulmonary arterial hypertension; left ventricular hypertrophy; right ventricular maladaptation; right ventricular remodeling; right ventricular-pulmonary arterial coupling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Cardiomyopathy, Dilated*
  • Growth Differentiation Factor 15
  • Humans
  • Hypertension, Pulmonary* / complications
  • Hypertension, Pulmonary* / diagnosis
  • Hypertrophy, Left Ventricular
  • Interleukin-1 Receptor-Like 1 Protein
  • Ventricular Dysfunction, Right* / diagnosis

Substances

  • Interleukin-1 Receptor-Like 1 Protein
  • Growth Differentiation Factor 15
  • Biomarkers